The landscape of medical weight management has undergone a historic revolution with GLP-1 receptor agonists like semaglutide and tirzepatide. Yet for millions of patients, these medications present a challenging hurdle: persistent gastrointestinal distress. Real-world clinical registry data indicate that up to 15% of individuals discontinue GLP-1 therapy entirely due to severe nausea, vomiting, or diarrhea.
Now, a completely distinct hormonal pathway is stepping into the clinical spotlight. Published in The Lancet Diabetes & Endocrinology, findings from a landmark Phase 2 trial demonstrate that an investigational compound named petrelintide achieves clinically meaningful weight loss while producing rates of vomiting and diarrhea virtually indistinguishable from an inactive placebo. By mimicking amylin—a natural pancreatic satiety hormone—rather than gut incretins, petrelintide may offer a well-tolerated alternative for individuals unable to take GLP-1 drugs.
What Is Petrelintide and How Does It Work?
To understand why petrelintide behaves differently from existing weight-loss injections, it helps to examine where natural satiety signals originate. Current blockbuster obesity medications stimulate receptors for glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), hormones secreted predominantly by enteroendocrine cells in the lower gut.
In contrast, petrelintide is a long-acting synthetic analogue of amylin. Natural human amylin is a 37-amino-acid peptide co-secreted with insulin by pancreatic beta cells during meals. While endogenous amylin breaks down in minutes, petrelintide features an extended elimination half-life of approximately 10 days, allowing steady once-weekly subcutaneous dosing.
Mechanistically, amylin acts through distinct neuroanatomical pathways. As metabolic researchers Professor Sten Madsbad and Professor Jens Juul Holst describe in The Lancet Diabetes & Endocrinology, amylin binds calcitonin receptors coupled with receptor activity-modifying proteins (RAMP1, RAMP2, RAMP3) in the area postrema and dorsal vagal complex within the brainstem.
When activated, amylin receptors orchestrate three primary physiological actions:
- Promoting meal satiety: Signaling the hindbrain to switch off appetite and enhance feelings of fullness.
- Moderating gastric emptying: Pacing stomach emptying to smooth postprandial glucose curves without causing severe stasis.
- Suppressing glucagon: Inhibiting post-meal glucagon secretion from pancreatic alpha cells, preventing liver glucose dumping.
Crucially, because amylin targets homeostatic satiety circuits rather than the visceral emetic pathways stimulated by GLP-1 receptors, research suggests petrelintide curbs appetite with substantially less nausea.
Inside the ZUPREME 1 Trial: Weight Loss Findings
The clinical efficacy of petrelintide was investigated in the ZUPREME 1 trial (NCT06662539). Led by Dr. W. Timothy Garvey and colleagues across 32 medical centers in Poland, Romania, and the United States, this multicentre, randomised, double-blind, placebo-controlled Phase 2 trial evaluated 485 adults with overweight or obesity.
The trial enrolled adults without type 2 diabetes with a body mass index (BMI) of at least 30 kg/m², or at least 27 kg/m² with hypertension or dyslipidemia. The cohort had a mean age of 47 years, a mean baseline body weight of 107.1 kg, and a mean BMI of 36.7 kg/m² (53% women). Participants were randomized to weekly subcutaneous petrelintide (1.0 mg, 2.5 mg, 5.0 mg, 7.0 mg, or 9.0 mg) or placebo for 42 weeks, including dose escalation.
Key Weight Loss Outcomes
At the primary 28-week endpoint, petrelintide demonstrated robust, dose-dependent weight reductions:
- Petrelintide 1.0 mg & 2.5 mg: -7.9% mean weight loss (treatment difference vs. placebo: -6.2%)
- Petrelintide 5.0 mg: -9.8% mean weight loss (treatment difference vs. placebo: -8.1%)
- Petrelintide 7.0 mg: -9.3% mean weight loss (treatment difference vs. placebo: -7.7%)
- Petrelintide 9.0 mg: -9.4% mean weight loss (treatment difference vs. placebo: -7.7%)
- Placebo: -1.7% mean weight loss
Weight continued to decline through week 42, reaching reductions of up to 10.7% on higher doses, establishing a direct causal effect on weight reduction under controlled clinical conditions.
Placebo-Like Digestive Tolerability
The trial’s most noteworthy finding was its adverse event profile. In the ZUPREME 1 trial, gastrointestinal side effects on petrelintide closely matched placebo across maintenance dosing:
- Vomiting: Occurred in only 3% (12 of 404) of petrelintide participants compared to 6% (5 of 81) on placebo.
- Diarrhea: Reported in 7% (30 of 404) on petrelintide versus 7% (6 of 81) on placebo.
- Constipation: Noted in 7% (28 of 404) on petrelintide versus 4% (3 of 81) on placebo.
- Nausea: Observed in 20% (79 of 404) of petrelintide participants versus 6% on placebo, predominantly mild and transient during dose escalation.
Importantly, only 6 of 404 participants (1.5%) discontinued petrelintide due to digestive adverse events, compared to typical 8% to 15% discontinuation rates reported with GLP-1 medications in real-world practice.
Comparing Next-Gen Amylin and GLP-1 Therapies
The table below summarizes clinical distinctions between petrelintide and standard GLP-1 therapy:
| Therapeutic Parameter | Petrelintide (ZUPREME 1) | Semaglutide 2.4 mg (STEP 1) |
|---|---|---|
| Hormone Class | Long-acting human amylin analogue | GLP-1 receptor agonist |
| Primary Target | Calcitonin receptor + RAMP1/2/3 (Area Postrema) | GLP-1R (Enteric, Vagal, Hypothalamus) |
| Mean Weight Loss | Up to 9.8% (week 28) / 10.7% (week 42) | 14.9% (week 68) |
| Vomiting Incidence | 3% (vs. 6% on placebo) | 24% (vs. 6% on placebo) |
| Diarrhea Incidence | 7% (vs. 7% on placebo) | 30% (vs. 16% on placebo) |
| GI Discontinuation | 1.5% of treated participants | 4.5% to 7.0% in trials |
| Regulatory Status | Investigational (Completed Phase 2) | FDA-approved prescription medication |
Source: Compiled from peer-reviewed clinical trial data in The Lancet Diabetes & Endocrinology (Garvey et al., 2026) and NEJM (Wilding et al., STEP 1).
Limitations and Next Steps
While Phase 2 results are encouraging, critical limitations remain. Petrelintide is an investigational drug not yet approved by the FDA or EMA. Larger Phase 3 trials are required to confirm multi-year efficacy, cardiovascular outcomes, and metabolic durability.
Additionally, the ZUPREME 1 cohort was predominantly White (86%) and excluded individuals with type 2 diabetes. Future studies must evaluate glycemic impact in diabetic populations. It is also unclear whether patients with severe GLP-1 intolerance can switch to amylin agonists without experiencing gastrointestinal symptoms, though different receptor pathways provide biological promise.
Researchers are also evaluating combination therapies pairing low-dose amylin agonists with GLP-1 medications, aiming to maximize weight loss while keeping side effects minimal.
The Bottom Line
For individuals who cannot tolerate GLP-1 medications due to severe gastrointestinal side effects, petrelintide represents a promising advance in obesity medicine. By leveraging pancreatic amylin rather than gut incretins, future treatments may achieve effective weight reduction with markedly improved daily tolerability. Always consult a qualified healthcare provider regarding personalized weight management options.
Related Reading
- GLP-1 Drugs and Gastroparesis: What Research Shows
- Stopping GLP-1s: What New Trials Reveal About Weight Regain
- Retatrutide Phase 3 Results: What the Triple Agonist Shows
Sources and Further Reading
- Garvey WT, Ard J, Connery L, et al. Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Diabetes & Endocrinology. 2026. PubMed PMID: 42810355.
- Madsbad S, Holst JJ. Petrelintide and the evolving role of amylin agonism in obesity. The Lancet Diabetes & Endocrinology. 2026. PubMed PMID: 42810353.
- Zealand Pharma / DOM Clinical Study Group. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials. Diabetes, Obesity and Metabolism. 2026. PubMed PMID: 42017294.
- Bagger JI, et al. Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs. Pharmacological Research. 2026. PubMed PMID: 42586227.
- Medical News Today. Early research suggests petrelintide may have fewer GI effects than GLP-1s. Published October 24, 2026. Medical News Today Report.
Disclosure: This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.